BIBvsIVV
ProShares Ultra Nasdaq Biotechnology against iShares Core S&P 500 ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | IVV | |
|---|---|---|
| Expense ratio | 0.95% | 0.030% |
| Assets | $104M | $889.4B |
| Net flow, 1 month | +$2M | −$6.7B |
| Net flow, 1 year | −$10M | +$97.3B |
| Return, YTD | +53.4% | +12.1% |
| Return, 1 year | +115.2% | +18.6% |
| Avg daily volume | 11K | 4.5M |
| Holdings | 229 | 507 |
| Listed | Apr 8, 2010 | May 14, 2000 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS